#SFHS2607766ADecree of 26 March 2026 amending the list of pharmaceutical specialties approved for use by public bodies and various public services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree adds one medicine to the official list of pharmaceutical specialties approved for use by public collectives and various public services. The product added is Imurel 50 mg film-coated tablets (azathioprine) in packs of 100 tablets, produced by Laboratoires DIFARMED SLU, with CIP code 34009 490 058 4. Only the therapeutic indications listed in its marketing authorisation (AMM) at the date of publication qualify for reimbursement by French health insurance. The decree was published on 31 March 2026 and takes immediate effect upon publication in the Journal officiel.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of Imurel 50 mg (azathioprine) film-coated tablets (B/100), CIP code 34009 490 058 4, to the approved list for public bodies
- Only therapeutic indications listed in the marketing authorisation (AMM) as of 31 March 2026 qualify for health insurance reimbursement
- Decree published on 31 March 2026 and effective immediately upon publication in the Journal officiel
+ 2 more changes with Pro
Obligations
What this law requires
Add Imurel 50 mg film-coated tablets (azathioprine) in packs of 100 tablets, produced by Laboratoires DIFARMED SLU (CIP code 34009 490 058 4) to the official list of pharmaceutical specialties approved for use by public collectives and public services
Limit reimbursement by French health insurance (assurance maladie) for Imurel 50 mg to only those therapeutic indications listed in its marketing authorisation (AMM) as of 31 March 2026
Publish this decree in the Journal officiel de la République française
Apply the decree immediately upon publication in the Journal officiel without requiring any additional implementation period